JP2012516842A - 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物 - Google Patents

代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物 Download PDF

Info

Publication number
JP2012516842A
JP2012516842A JP2011547063A JP2011547063A JP2012516842A JP 2012516842 A JP2012516842 A JP 2012516842A JP 2011547063 A JP2011547063 A JP 2011547063A JP 2011547063 A JP2011547063 A JP 2011547063A JP 2012516842 A JP2012516842 A JP 2012516842A
Authority
JP
Japan
Prior art keywords
composition
protein
pharmaceutical
mixtures
fractions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011547063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516842A5 (https=
Inventor
ビューパチラジュ，キラン
ゴカラジュ，ガンガ，ラジュ
ゴカラジュ，ラマ，ラジュ
ゴカラジュ，ベンカタ，カナカ，ランガ，ラジュ
ゴラコチ，トリムーツル
セングプタ，クリシャヌ
アルリ，ベンカタ，クリシュナ，ラジュ
Original Assignee
ライラ ニュートラシューティカルズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライラ ニュートラシューティカルズ filed Critical ライラ ニュートラシューティカルズ
Publication of JP2012516842A publication Critical patent/JP2012516842A/ja
Publication of JP2012516842A5 publication Critical patent/JP2012516842A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
JP2011547063A 2009-02-02 2010-02-01 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物 Pending JP2012516842A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN224/CHE/2009 2009-02-02
IN224CH2009 2009-02-02
PCT/IN2010/000053 WO2010100653A2 (en) 2009-02-02 2010-02-01 Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome

Publications (2)

Publication Number Publication Date
JP2012516842A true JP2012516842A (ja) 2012-07-26
JP2012516842A5 JP2012516842A5 (https=) 2012-12-27

Family

ID=42710066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011547063A Pending JP2012516842A (ja) 2009-02-02 2010-02-01 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物

Country Status (8)

Country Link
US (3) US9241964B2 (https=)
EP (1) EP2391374B1 (https=)
JP (1) JP2012516842A (https=)
KR (1) KR101682489B1 (https=)
CN (1) CN102292093B (https=)
AU (1) AU2010220058B2 (https=)
CA (1) CA2751227C (https=)
WO (1) WO2010100653A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
JP2014034562A (ja) * 2012-08-10 2014-02-24 Lotte Kenko Sangyo:Kk アディポネクチン産生促進剤
JP2015017051A (ja) * 2013-07-10 2015-01-29 和久 前田 メタボリックシンドローム治療剤
JP2018520193A (ja) * 2015-07-24 2018-07-26 山▲トゥン▼新薬開発股▲ふん▼有限公司 皮膚疾患治療薬を製造するためのマンゴスチン果皮抽出物の用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
ME01898B (me) 2008-08-12 2014-12-20 Zinfandel Pharmaceuticals Inc Metoda za identifikaciju faktora rizika od alchajmerove bolesti
PH12013500451A1 (en) * 2010-09-11 2013-05-20 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
JP5976271B2 (ja) * 2010-12-24 2016-08-23 クラシエホームプロダクツ株式会社 リパーゼ阻害剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
KR101508294B1 (ko) * 2012-07-05 2015-04-07 동국대학교 산학협력단 망고스틴 추출물 또는 감마, 알파 망고스틴을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 조성물
WO2014064609A2 (en) * 2012-10-23 2014-05-01 Piramal Enterprises Limited HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES
US20140377386A1 (en) * 2013-06-19 2014-12-25 Access Business Group International Llc Plant-based inhibitors of ketohexokinase for the support of weight management
TWI565472B (zh) * 2016-02-02 2017-01-11 基業生物科技股份有限公司 山竹組合物及其製備增進阿茲海默症患者學習能力與記憶的藥物及保健食品之用途
BR112018073483B1 (pt) * 2016-05-21 2022-08-23 Laila Impex Suplementos e composições dietéticas para a melhoria do desempenho físico e dos níveis de energia
CN111773208A (zh) * 2019-09-20 2020-10-16 厦门医学院 藤黄属果实萃取物γ-倒捻子素在制备降血糖及降血压的药物组合物中的应用
CN111758967B (zh) * 2020-07-15 2022-10-11 张兆熙 一种大鲵胶原蛋白肽组合物及其应用
CN118873430B (zh) * 2024-08-16 2025-04-04 诺德溯源(广州)生物科技有限公司 一种敏感肌适用的植物a醇祛皱紧致组合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774905A1 (fr) * 1998-02-17 1999-08-20 Codif International Sa Utilisation d'une composition cosmetique comportant au moins une substance qui comprend un groupement pyrone
JP2002047125A (ja) * 2000-05-26 2002-02-12 Shiseido Co Ltd 皮脂分泌抑制用皮膚外用剤
JP2003508467A (ja) * 1999-09-08 2003-03-04 メド−イーキュー エーエス アルファ−アミラーゼインヒビターと、腸からの「速効性糖類（ｆａｓｔｓｕｇａｒｓ）」の吸収を減少させるために適する少なくとも一種類の生理学的に許容可能な化合物とを含む組成物
JP2005298379A (ja) * 2004-04-08 2005-10-27 Lotte Co Ltd ＩκＢキナーゼ阻害剤
JP2005295991A (ja) * 2004-03-18 2005-10-27 Sakamoto Yakusoen:Kk Ｐｐａｒ活性化作用を有する健康食品およびｐｐａｒ活性化剤
WO2007036900A2 (en) * 2005-09-30 2007-04-05 Piramal Life Sciences Limited Herbal composition for inflammatory disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3647054B2 (ja) * 1993-11-12 2005-05-11 御木本製薬株式会社 抗酸化剤
JPH09110688A (ja) * 1995-10-13 1997-04-28 Meiji Milk Prod Co Ltd 抗菌剤
DE60309075D1 (de) * 2003-03-31 2006-11-23 Council Scient Ind Res Verfahren zur herstellung hypoglykämischer lebensmittel und formulierungen daraus
ES2559777T3 (es) * 2004-03-17 2016-02-15 Nestec S.A. Composiciones y métodos para reducir o prevenir la obesidad
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
SI1931366T1 (sl) * 2005-09-30 2013-10-30 Piramal Enterprises Limited Zeliščni sestavek proti vnetnim motnjam
FR2908310B1 (fr) 2006-11-14 2009-07-10 Phytodia Produits agonistes de tgr5 et leurs applications
WO2008093848A1 (ja) 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774905A1 (fr) * 1998-02-17 1999-08-20 Codif International Sa Utilisation d'une composition cosmetique comportant au moins une substance qui comprend un groupement pyrone
JP2003508467A (ja) * 1999-09-08 2003-03-04 メド−イーキュー エーエス アルファ−アミラーゼインヒビターと、腸からの「速効性糖類（ｆａｓｔｓｕｇａｒｓ）」の吸収を減少させるために適する少なくとも一種類の生理学的に許容可能な化合物とを含む組成物
JP2002047125A (ja) * 2000-05-26 2002-02-12 Shiseido Co Ltd 皮脂分泌抑制用皮膚外用剤
JP2005295991A (ja) * 2004-03-18 2005-10-27 Sakamoto Yakusoen:Kk Ｐｐａｒ活性化作用を有する健康食品およびｐｐａｒ活性化剤
JP2005298379A (ja) * 2004-04-08 2005-10-27 Lotte Co Ltd ＩκＢキナーゼ阻害剤
WO2007036900A2 (en) * 2005-09-30 2007-04-05 Piramal Life Sciences Limited Herbal composition for inflammatory disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6014004943; Ｉｎｄｉａｎ　Ｐｈａｒｍａｃｉｓｔ Ｖｏｌ．７，　Ｎｏ．７３, 2008, ｐ．７５-７８ *
JPN6014004945; Ｐｈａｒｍａｃｙ　ａｎｄ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．６０, 2008, ｐ．９０９-９１６ *
JPN6014004948; Ｔｅｎｐｅ，　Ｃ．　Ｒ．；　Ｕｐａｇａｎｌａｗａｒ，　Ａ．　Ｂ．；　Ｎａｙａｋ，　Ｓ．　Ｈ．；　Ｙｅｏｌｅ，　Ｐ．　Ｇ．: 'Ｅｆｆｅｃｔ　ｏｆ　Ｓｐｈａｅｒａｎｔｈｕｓ　ｉｎｄｉｃｕｓ　Ｌｉｎｎ．　ｏｎ　ｌｉｐｉｄ　ｐｒｏｆｉｌｅ　ｉｎ　ｄｅｘａｍｅｔｈａｓｏｎｅ　ｉｎｄｕｃｅｄ　ｒａｔｓ．' Ｂｉｏｍｅｄ Ｖｏｌ．２，　Ｎｏ．４, 2008, ｐ．４００-４０３ *
JPN6014004950; Ａｒｓ　Ｐｈａｒａｍａｃｅｕｔｉｃａ Ｖｏｌ．４５，　Ｎｏ．３, 2004, ｐ．２８１-２９１ *
JPN6014004952; Ｉｎｄｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｂｉｏｌｏｇｙ Ｖｏｌ．４４, 2006, ｐ．９９３-９９６ *
JPN6014004954; Ｊ．　Ａｇｒｉｃ．　Ｆｏｏｄ　Ｃｈｅｍ． Ｖｏｌ．５５, 2007, ｐ．９８０５-９８１０ *
JPN6014004956; Ｆｏｏｄ　ａｎｄ　Ｃｈｅｍｉｃａｌ　Ｔｏｘｉｃｏｌｏｇｙ Ｖｏｌ．４６, 2008, ｐ．３２２７-３２３９ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
JP2014034562A (ja) * 2012-08-10 2014-02-24 Lotte Kenko Sangyo:Kk アディポネクチン産生促進剤
JP2015017051A (ja) * 2013-07-10 2015-01-29 和久 前田 メタボリックシンドローム治療剤
JP2018520193A (ja) * 2015-07-24 2018-07-26 山▲トゥン▼新薬開発股▲ふん▼有限公司 皮膚疾患治療薬を製造するためのマンゴスチン果皮抽出物の用途

Also Published As

Publication number Publication date
US10471114B2 (en) 2019-11-12
CA2751227A1 (en) 2010-09-10
EP2391374A4 (en) 2014-01-08
EP2391374A2 (en) 2011-12-07
WO2010100653A8 (en) 2011-08-04
KR20110122158A (ko) 2011-11-09
US9241964B2 (en) 2016-01-26
EP2391374B1 (en) 2018-11-14
US20130136809A1 (en) 2013-05-30
CN102292093B (zh) 2015-01-28
AU2010220058B2 (en) 2016-02-18
CN102292093A (zh) 2011-12-21
AU2010220058A1 (en) 2011-07-21
KR101682489B1 (ko) 2016-12-05
WO2010100653A3 (en) 2010-11-04
US20160074457A1 (en) 2016-03-17
WO2010100653A2 (en) 2010-09-10
US20110280951A1 (en) 2011-11-17
CA2751227C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
US10471114B2 (en) Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome
Huang et al. Identification of compounds in adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) seed hull extracts that inhibit lipopolysaccharide-induced inflammation in RAW 264.7 macrophages
US8703215B2 (en) Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases
US9345732B2 (en) Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
US20060078632A1 (en) Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease
JP2013508352A (ja) アセトゲニンを含む抽出物、フラクションおよび組成物ならびにそれらの応用
KR20180003073A (ko) 새싹보리 추출물을 포함하는 비만 치료 또는 예방용 조성물
CN105744942A (zh) 五层龙组合物，通过其施用的治疗方法，及其制备方法
KR20080003931A (ko) 인슐린 저항성 증후군의 치료
US20080175888A1 (en) Combination Therapy Comprising Actinidia and Steroids and Uses Thereof
MX2007010408A (es) Composiciones que comprenden actinidia y sus metodos de uso.
JP5864003B1 (ja) 脂質蓄積抑制効果を有する新規羅漢果抽出物組成物
KR20240025853A (ko) 까마중 추출물을 유효성분으로 포함하는 면역증진 및 항비만용 조성물
KR20110138732A (ko) 참죽나무 추출물을 함유하는 항염증 조성물
KR20230092134A (ko) 금화규의 저온 추출물을 유효성분으로 포함하는 항비만용 조성물
HK1159520A (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
HK1159520B (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
KR101059308B1 (ko) 불가사리 추출 분획물을 유효성분으로 함유하는 염증 또는알러지 질환의 예방 및 치료용 조성물
KR20170142223A (ko) 알카닌을 유효성분으로 포함하는 대사성 질환용 조성물
KR20240114326A (ko) 식물 복합추출물을 유효성분으로 포함하는 항염증용, 항산화용 및 근 기능 개선용 조성물
KR101557557B1 (ko) 엔드리케리아 아노말라 추출물을 포함하는 항비만 조성물
KR20130072661A (ko) 와송의 디클로로메탄 분획물을 유효성분으로 포함하는 항염증 조성물
TW201102077A (en) Extracts of Eleutherococcus spp., preparation method thereof and use of the same
JP2010265182A (ja) 高脂血症及び肥満の予防改善用組成物
JP2011178796A (ja) 脂肪吸収抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141023

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141203

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160413